Adlib and Generis launch software connector to increases automation and compliant management of document repositories

CARA is a data and content management platform that helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes

Zydus receives final approval from the USFDA for Sucralfate Tablets USP, 1 gram

Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022

Therapy recently approved in Canada under the brand name KORSUVA

Kapruvia approved by European Commission for hemodialysis patients

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients

Enteris BioPharma gets featured on its oral drug delivery technology

Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights

U.S. FDA approval of KORSUVA injection

First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).

Balaxi Pharmaceuticals Q1 revenue increases by 12%

The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY

Balaxi records Q4 FY21 revenue of Rs. 53 Cr

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday